{
    "nctId": "NCT01137136",
    "briefTitle": "Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea",
    "officialTitle": "Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea",
    "overallStatus": "SUSPENDED",
    "conditions": "Polymorphism, CYP19, Aromatase Inhibitor",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "The prevalence of CYP19 polymorphism",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* hormone receptor positiveBreast cancer patient\n* postmenopausal women\n* first user of aromatase inhibitor\n\nExclusion Criteria:\n\n* premenopausal\n* The patient who take the other antihormonal therapy\n* osteoporosis patients",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}